NFKB1 and Miyoshi myopathy: The success of the drugs mentioned above in MM and DLBCL cannot be replicated in other tumor treatments, suggesting NF‐κB has universal and complicated functions that could not be a fixed therapeutic target like PD‐1/PD‐L.